Longeveron (LGVN) FCF Margin (2020 - 2026)
Longeveron (LGVN) recorded quarterly FCF Margin of 1097.99% in Q1 2026, up 24.33% quarter-over-quarter from 1450.96% in Q4 2025, and up 14191.0% on a YoY basis from N/an in Q1 2025.
Longeveron (LGVN) FCF Margin (2020 - 2026) Analysis & Trends
Longeveron's FCF Margin history runs 7 years deep, the most recent figure standing at 1097.99% for Q1 2026.
- In Q1 2026, FCF Margin rose 14191.0% year-over-year to 1097.99%; the TTM figure through Mar 2026 stood at 1524.34% (down 79872.0% YoY), while the FY2025 annual figure was 1575.48%, down 96833.0% from the prior year.
- FCF Margin was 1097.99% for Q1 2026 at Longeveron, up from 1450.96% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 423.42% in Q3 2024 to a low of 6604.76% in Q4 2023.
- Historically, FCF Margin has averaged 1977.9% across 5 years, with a median of 1239.9% in 2025.
- The sharpest annual moves came in 2023 and 2024: FCF Margin slumped 464278 bps in 2023, then surged 604324 bps in 2024.
- A 5-year view of FCF Margin shows it stood at 1961.98% in 2022, then plunged by 237 bps to 6604.76% in 2023, then surged by 91 bps to 561.53% in 2024, then plunged by 158 bps to 1450.96% in 2025, then gained by 24 bps to 1097.99% in 2026.
- The last three FCF Margin figures came in at 1097.99% (Q1 2026), 1450.96% (Q4 2025), and 3731.39% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -1,097.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,097.99% |
| Dec 31, 2025 | -1,450.96% |
| Sep 30, 2025 | -3,731.39% |
| Jun 30, 2025 | -1,189.24% |
| Mar 31, 2025 | -1,239.90% |
| Dec 31, 2024 | -561.53% |
| Sep 30, 2024 | -423.42% |
| Jun 30, 2024 | -1,017.52% |
| Mar 31, 2024 | -566.06% |
| Dec 31, 2023 | -6,604.76% |
| Sep 30, 2023 | -3,039.33% |
| Jun 30, 2023 | -2,162.67% |
| Mar 31, 2023 | -2,111.11% |
| Dec 31, 2022 | -1,961.98% |
| Sep 30, 2022 | -4,612.00% |
| Jun 30, 2022 | -719.53% |
| Mar 31, 2022 | -1,134.86% |
| Dec 31, 2021 | -762.20% |
| Sep 30, 2021 | -1,021.98% |
| Jun 30, 2021 | -603.68% |